vonapanitase
Phase 3- Indications
- Hemodialysis vascular access, Peripheral artery disease
Company intelligence / Profile preview
Laminate’s VasQ™ device has demonstrated improved outcomes over standard care for arteriovenous fistula creation in hemodialysis patients. Clinical studies—including randomized controlled trials—show higher rates of successful AVF maturation and reduced need for additional procedures. The device received FDA Breakthrough Device designation, De Novo clearance, and CMS Transitional Pass-through Payment status. It is commercially available across the US, Europe, UK, Africa, and Singapore.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Laminate Medical Technologies.